A Network Meta-Analysis of Clinical Management Strategies for Treatment-Resistant Hypertension: Making Optimal Use of the Evidence by Makai, P. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/177330
 
 
 
Please be advised that this information was generated on 2020-09-08 and may be subject to
change.
REVIEW
A Network Meta-Analysis of Clinical Management Strategies
for Treatment-Resistant Hypertension: Making Optimal Use
of the Evidence
Peter Makai, PhD1, Joanna IntHout, PhD1, Jaap Deinum, MD PhD1, Kevin Jenniskens, MSc2, and
Gert Jan van der Wilt, PhD1
1Department for Health Evidence, Health Technology Assessment Group, Radboud Institute for Health Sciences, Radboud University Medical
Center, Nijmegen, The Netherlands; 2Julius Center, University Medical Center Utrecht, Utrecht, The Netherlands.
BACKGROUND: With the addition of surgical interven-
tions to current medicinal treatments, it is increasingly
challenging for clinicians to rationally choose among the
various options for treating patients with apparent
treatment-resistant hypertension (ATRHTN).
This study aims to establish the comparative effectiveness
of mineralocorticoid receptor antagonists (MRA), renal
denervation (RDN), darusentan and central arteriovenous
anastomosis (CAA) for patients with ATRHTN by
performing a network meta-analysis.
METHODS:
Data Sources: Studies from recent meta-analyses for
RDN and placebo effect were supplemented with a sys-
tematic search for MRAs in ATRHTN in the Pubmed,
EMBASE, CINAHL and Cochrane databases through No-
vember 2016.
Study Selection: Randomized controlled trials compar-
ing treatment options for patients with ATRHTN.
Data Extraction and Synthesis: Data were extracted
using predefined data extraction forms, including the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) criteria. A Bayesian random ef-
fectsmodelwasused to conduct a networkmeta-analysis.
Spironolactone was used as the main comparator.
Main Outcomes and Measures: Reduction in 24-h am-
bulatory blood pressure measurement (ABPM).
RESULTS: Twenty articlesmet our inclusion criteria, and
seven treatment alternatives were compared. Compared
to MRA, CAA had the highest probability of being more
effective, further reducing 24-h SBP (−4.8 mmHg [−13.0,
3.7]) and 24-h DBP (−9.7 mmHg [−18, -0.63]). This differ-
ence is likely to be clinicallymeaningful, with a probability
of 78 and 96% at a threshold of a 2-mmHg reduction in
blood pressure.
CONCLUSIONS: When compared to MRA as anchor,
darusentan, CAA and RDN are not more effective in
achieving a clinically significant reduction in ambulatory
blood pressure in individuals with apparent treatment-
resistant hypertension.
KEY WORDS: treatment-resistant hypertension; network meta-analysis;
MRAs.
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INTRODUCTION
Hypertension (HTN) is the most common condition seen in
primary care,1 with a global prevalence of 41% in the general
population.2 Uncontrolled HTN is a risk factor for cardiovas-
cular and renal disease, sources of significant morbidity and
cost to society, and is therefore an important public health
target.1,3,4 An estimated 14–16% of hypertensive patients have
apparent treatment-resistant hypertension (ATRHTN).5 This
proportion will be even higher if more stringent criteria are
adopted for adequate blood pressure control.6–9 ATRHTN is
defined as inadequately controlled blood pressure despite
receiving three or more adequately dosed hypertensive medi-
cations, of which at least one is a diuretic.10 Adherence is a key
factor in ATRHTN, and according to some estimates, 50% of
patients with ATRHTN do not adhere to their medication.11–13
The most common fourth-line treatment is the addition of a
mineralocorticoid receptor antagonist (MRA) to the treatment
regimen.14 In recent years, other pharmacological interven-
tions have been developed, including darusentan,15 an
endothelin receptor antagonist, as well as various device-
based strategies such as renal denervation (RDN) and central
arteriovenous anastomosis (CAA).16
A lack of data on the comparative effectiveness of these
new treatment strategies poses challenges to the production
and interpretation of relevant clinical evidence and to choosing
optimal treatment strategies for patients. Direct comparison
trials and conventional pairwise meta-analyses have demon-
strated different conclusions regarding the efficacy of RDN,
likely because of the heterogeneity in control treatments. Trials
of RDN, for example, have compared RDN with standard
medication therapy (no additional treatment),17 with a sham
procedure (mimicking RDN without actually performing the
intervention)18 and with MRA as add-on therapy.19 While a
recent medium-sized trial showed that RDN was superior to
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MRA,19 another trial of the same size failed to show a differ-
ence in the primary endpoint.20 Among direct comparisons of
RDN with other active treatments, results have been mixed.
Three conventional pairwise meta-analyses show RDN to be
superior,17,21,22 while a fourth meta-analysis, based exclusive-
ly on randomized controlled trials (RCTs), casts doubt on
these conclusions.23
Conventional pairwise meta-analysis is unable to deal with
heterogeneity in control interventions. A more appropriate
approach in such cases is a network meta-analysis.24 In a
network-meta analysis, effect sizes associated with direct and
indirect comparisons can be estimated for all treatment strate-
gies in the network.25 For example, in the case of ATRHTN, if
trials have been reported comparing spironolactone (an MRA)
with RDN and with darusentan, but no trials have been report-
ed comparing darusentan to RDN directly, an indirect com-
parison can be made by using the results of the trials in which
each was compared with darusentan.25 Typically, all compar-
isons within a network meta-analysis are anchored to a place-
bo or to a widely accepted active comparator. Using this
anchor, it is possible to determine the relative effects of any
comparator in the network.
Network meta-analyses can be performed within a compar-
ative effectiveness framework. The main question in this case
is not simply whether a new therapy is effective, but whether it
is substantially superior to the current standard of care. In the
field of ATRHTN, guidelines recommendMRAs,26 and there-
fore we consider this the most suitable anchor within this
population.
The aim of this study is to use network meta-analysis to
estimate the comparative effectiveness of the third-line hyper-
tensive therapies darusentan, CAA and RDN, compared to a
mineralocorticoid receptor antagonist anchor, in reducing sys-
tolic and diastolic blood pressure (SBP and DBP, respectively)
in patients with ATRHTN.
METHODS
Study Identification and Data Extraction
The study was registered in the PROSPERO database, speci-
fying the inclusion criteria and methods used27 (PROSPERO
2015:CRD42015017323; available from http://www.crd.york.
a c . u k / P R O S P E R O / d i s p l a y _ r e c o r d . a s p ?
ID=CRD42015017323). To be included in the network meta-
analysis, studies were required to meet the following criteria:
1) the study was an RCT; 2) treatment or control treatment
were MRA, RDN or placebo (independent of active compar-
ison); 3) the study population comprised patients with
treatment-resistant hypertension, defined as uncontrolled hy-
pertension despite receiving three or more antihypertensive
medications, of which at least one is a diuretic; 4) the study
was published in English; and 5) the study reported 24-h blood
pressure obtained by ambulatory blood pressure measurement
(ABPM) for SBP and DBP outcomes (absolute or relative to
baseline).
Pubmed, EMBASE, CINAHL and Cochrane databases
were systematically searched for relevant articles in November
2016. The search terms and strategy are presented in detail in
the Online Appendix. PM andKJ independently assessed titles
and abstracts, and subsequently selected full-text articles. Re-
cords were assessed for eligibility and were excluded in the
case of disease condition other than ATRHTN, studies not
reporting primary clinical data, or case studies. In addition,
two recent systematic reviews on MRAs,28,29 four recent
meta-analyses of RDN17,21–23 and one meta-analysis on pla-
cebo effect in the ATRHTN population30 were checked for
relevant references. PM and KJ independently extracted rele-
vant data using a pre-specified form. Main summary measures
extracted were study characteristics and average 24-h ABPM.
In addition, we extracted data onmean age, sex, study duration
and inclusion criteria. Further outcomes extracted were office
SBP and DBP (see Online Appendix). For all selected articles,
PM and KJ assessed the risk of bias using the Cochrane risk of
bias tool31 and the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) criteria.32 All dis-
crepancies between the coders were resolved by consensus.
Analysis
For the main analysis in the quantitative synthesis, we includ-
ed studies reporting 24-h ABPM, and excluded studies
reporting only office BPM. We have focused on 24-h ABPM,
because high-quality evidence was available, and the measure-
ment is more precise and reliable than office BPM. Office
BPM was analyzed in a sensitivity analysis. We used a Bayes-
ian random effects network meta-analysis approach to analyze
the data, and meta-regression adapted for multiple treatment
comparisons. Using meta-regressions, we controlled for the
effect of differences in the previously identified variables
baseline blood pressure and number of medications used.30
Based on the search, the main treatment strategies assigned to
the network nodes were: RDN, MRAs (spironolactone and
eplerenone), placebo, sham, darusentan, CAA and regimens
having more than 3 medications without an add-on. We relate
SBP and DBP reduction to the minimum clinically important
difference of 2 mmHg.33
We used R version 3.3.134 for the analysis, specifically the
GeMTC package version 0.8.135 for the meta-analysis.36,37
The network st ructure was generated using the
mtm.networkplot.fun function in R.38 We estimated heteroge-
neity across the network using I2. Avalue of I2 below 40%was
considered acceptable, while values above 75% were consid-
ered as evidence of considerable heterogeneity.31 Meta-
regression was used to investigate the impact of imbalance in
the covariates baseline blood pressure and number of co-
medications used, in order to adjust for possible between-
study confounders and intransitivity.24 We also investigated
inconsistency using a node-splitting approach.39 Consistent
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with the use of Bayesian analyses, we report 95% credibility
intervals instead of confidence intervals. A 95% credibility
interval signifies that there is a 95% probability that the true
value lies between the lower and the upper bounds. Thus, our
analysis allowed for estimation of the probability that a spe-
cific add-on treatment would result in a clinically important
lowering of blood pressure in patients with ATRHTN com-
pared to a specified alternative. Details on the estimation
procedure are presented in the Online Appendix. Reporting
is in accordance with Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines.40,41
RESULTS
Study Selection, Characteristics and Risk of Bias
Database searches resulted in 1204 records, and 14 additional
records were identified through cross-referencing of previous-
ly published meta-analyses (Figure A1). After the removal of
duplicates, 984 unique records remained. Twenty studies met
the inclusion criteria. Study characteristics are presented in
Table 1. The 20 studies allowed comparison of ten medicinal
or non-medicinal treatment strategies in the quantitative syn-
thesis. Eplerenone and spironolactone were combined, and a
single study with vitamin D was removed from the main
analysis due to its ineffectiveness compared with placebo.42
Figure A2 shows the risk of bias per study, while Figure A3
shows the risk of bias across studies, according to the GRADE
criteria. The studies investigating device-based interventions
in particular were not adequately blinded, lacking a sham-
controlled study arm.
Results of Individual Studies
Table 2 shows the results of the individual studies. All treat-
ments significantly reduced blood pressure compared to base-
line values. This was also true for the control groups in 8 of the
19 studies, independently of whether an active comparator
was used. The between-group difference in 24-h SBP reduc-
tion was statistically significant in all studies with the excep-
tion of Mathiassen,46 Kario,44 and SYMPLICITY HTN-3.18
This difference was also clinically relevant (blood pressure
reduction of 2 mmHg or more) in 13 of the 19 studies. In terms
of DBP, there were significant differences in the majority of
the studies, the exceptions being the studies by Mathiassen,46
Kario,44 Desch,45 Azizi19 and Oxlund.49 In 9 of the 19 studies,
the between-group differences were clinically relevant.
Synthesis of the Results
The network structure is presented in Figure 1. All treatments
were add-on therapies, offered to patients with ATRHTN in
addition to three or more medications. The size of the circles
represents the number of patients per alternative in the net-
work; the lines between the circles show the direct compari-
sons in the network, with the thickness representing the total
number of patients in the trials.
Figure 2 shows the results of the Bayesian random effects
network meta-analysis for the 24-h SBP outcome. Since blood
pressure reduction is the goal, negative numbers signify higher
reduction versus the comparator, and positive values signify a
relative increase in blood pressure. Figure 2a and b compares
all strategies to spironolactone, with associated 95% credibil-
ity intervals (95% CrI).
Figure 3a and b shows the probability of a clinically relevant
difference in blood pressure change compared to spironolactone
for the 24-h DBP outcome. In Figure 3a and b, the curved lines
signify the probability that the difference in blood pressure re-
duction is larger than the value indicated on the x-axis.
Effectiveness Compared to MRA. Compared to MRA,
darusentan, CAA, and RDN were not more effective in
lowering SBP in individuals with treatment-resistant hyper-
tension. (Fig. 2a). The differences in SBP reduction between
MRAs, RDN, darusentan and sham procedure were not clin-
ically relevant. MRAs were significantly more effective than
medication placebo (−13 mmHg [−9.9, -16.0]) and no addi-
tional treatment (−8.9 mmHg [−12.0, -5.7]), and these differ-
ences in SBP reduction were also clinically relevant. As
shown in Figure 2c, the only treatment that had a reasonable
probability of achieving a clinically relevant SBP reduction
greater than MRAs was CAA (72%).
For DBP, CAA, Darusentan and RDN achieved significant-
ly greater blood pressure reduction than MRAs (Fig. 2b).
Conversely, the difference in DBP reduction due to
spironolactone was not clinically relevant when compared
with the reduction achieved by darusentan, RDN, and sham
procedure. MRAs were significantly more effective than med-
ication placebo −4.4 mmHg [−2.4, -6.5]) and no additional
treatment −4.3 mmHg [−2.3, -6.1], and these differences were
also clinically relevant. As can be seen on Figure 2d, CAA
(92%) had a high probability of achieving a clinically relevant
DBP reduction greater than MRAs.
Effectiveness Compared to Sham Procedure. Figure A4
shows the comparisons using the sham procedure as an
anchor. For SBP, only RDN achieved a significantly greater
reduction than the sham procedure. Conversely, the difference
in SBP reduction due to the sham procedure was not clinically
relevant when compared to darusentan. Sham procedures were
more effective than medication placebo and no additional
treatment, and these differences were clinically meaningful.
As shown in Figure A4C, CAA (90%), RDN (82%) and
MRAs (75%) had a reasonable probability of achieving a
clinically relevant SBP reduction greater than sham. For
DBP, only CAA achieved a significantly greater reduction
than the sham procedure. The difference in DBP reduction
due to the sham procedure was not clinically relevant when
compared to darusentan, RDN and MRAs. Sham procedures
were significantly more effective than medication and no
additional treatment. As is evident from Figure A4D, CAA
923Makai et al.: Network Meta-Analysis of Resistant Hypertension TreatmentsJGIM
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(98%) had a reasonable probability of achieving a clinically
relevant DBP reduction greater than the sham procedure.
Risk of Bias Across Studies and Additional
Analyses
Heterogeneity in the study results was moderate, with I2 =
52.7% for SBP and I2 = 44.2% for DBP. The inclusion of
baseline covariates such as baseline blood pressure and num-
ber of medications used did not significantly impact the results
of the meta-analysis, nor could they account for the observed
heterogeneity. No evidence of publication bias was found.
Office SBP and DBP point estimates were broadly similar to
the 24-h ABPM results, with the exception of the CAA and
sham procedure results, and the uncertainty around these
estimates was much higher. Compared to the use of 24-h
SBP/DBP measurements as outcomes, a network meta-
analysis of office measurements resulted in a higher level of
heterogeneity (I2 = 61.2% for OSBP and I2 = 99% for ODBP
respectively). A sensitivity analysis, discarding studies with
Figure 1 Network structure of studies with available 24-h ABPM.
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more than three indicators of bias, did not produce results that
differed from the main analysis.
DISCUSSION
Summary of Evidence
Comparative Effectiveness. When compared to MRA as an
anchor, darusentan, CAA and RDNwere not more effective in
achieving a clinically significant reduction in ambulatory
blood pressure measurement in individuals with ATRHTN.
Most individual comparative trials testing a specific medical
or non-medical regimen in patients with treatment-resistant
hypertension have reported some, albeit variable, benefit in
terms of blood pressure control. However, the use of different
comparators, including no additional treatment, drug placebo,
sham procedure and active comparator, hampers the interpre-
tation of results across studies. Conventional meta-analyses to
date have been unable to resolve this problem, because by
lumping of control interventions, they ignore the heterogene-
ity of the comparators.17,21,22 A network meta-analysis can
accommodate this type of heterogeneity,24 enabling optimal
use of the available evidence to guide clinical management.
The results of such an approach here show that none of the
treatments included in this study resulted in a statistically
significant greater SBP reduction compared with MRAs. For
DBP, CAA resulted in a clinically relevant and statistically
significant greater reduction. The results also allow for an
estimate of the probability that either of these treatments result
in clinically relevant better blood pressure control. For 24-h
SBP, CAA has a 72% probability of resulting in better BP
control than MRAs. For 24-h DBP, this figure is 98%. With
such figures, individual clinicians and guideline committees
can weigh the probability of successful treatment against
potential side effects or cost-effectiveness in order to select
optimal treatments for patients with treatment-resistant hyper-
tension. An additional advantage of this type of analysis is that
such results might be interpreted more easily by patients,
facilitating patient–physician communication.
Effectiveness Compared to Placebo. Particular care needs to
be taken in interpreting the effectiveness of the interventions,
as significant and major differences were found between
medication placebo and sham procedure, another type of
placebo. Compared with medication placebo or no additional
treatment, MRAs significantly reduced both SBP and DBP.
The magnitude and the significance of the medication placebo
adjusted effect was similar to that in a recent study using home
blood pressure outcome measurement,57 and in line with the
effects found in recent meta-analyses.29,58 At the same time,
the effects of MRAs on SBP reduction did not differ from the
effects of a sham procedure, another kind of placebo. While
this may sound counterintuitive, these results are consistent
with the literature as far as the difference in effect size between
sham procedures and medication placebo both in this population
and in general,30,59,60 while both have a marked effect on
blood pressure reduction.30 It is possible that the enhanced
clinical routine61 surrounding a sham procedure increases
adherence to the background medications in these patients.
Figure 2 Estimated differences in mean 24-h SBP and DBP (mmHg)
reductions, including 95% credibility intervals (CrI). a Effectiveness
of the various treatment options on the SBP outcome compared to
MRA. b Effectiveness of the various treatment options on the DBP
outcome compared to MRA.
Figure 3 Probability of blood pressure change at various minimum
clinically important difference levels. a Probability of SBP change
versus MRA at various minimum clinically important difference
levels. b Probability of DBP change versus MRA at various
minimum clinically important difference levels.
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While it is likely that adherence to medication also improves
somewhat under trial conditions, such increased adherence is
less likely when an additional medication is introduced to an
already busy medication schedule of four chronic medications
on average. In any case, it seems appropriate to use a sham
procedure as an effectiveness benchmark in ATRHTN for
future interventions, as it appears to provide a common
benchmark for comparing both medication and device-based
treatment strategies.
Limitations
This review is not comprehensive, as it does not include all
possible treatments for ATRHTN, because not all treatment
strategies reported 24-h ABPM for the main analysis. We have
focused on 24-h ABPM, for which high-quality evidence was
available. In the overall GRADE assessment for the 24-h SBP
and DBP outcomes, we have not downgraded the studies, and
the quality of the evidence remains high. Using GRADE,
results for the office SBP/DBP outcome were downgraded
mainly due to imprecision and inconsistency (heterogeneity)
across studies. This imprecision may be due to the fact that
office blood pressure values are not particularly reliable, and
are prone to be influenced by white-coat effects.30 In addition,
inconsistency (heterogeneity) in office SBP and DBP was
substantial or considerable,31 leading to unreliable conclu-
sions. As a result, treatments reporting only office blood
pressure were excluded. Therefore, barostimulation therapy
could not be compared in the main analysis, nor could we
include the alpha blocker doxazosin or the beta blocker
bisoprolol reported in the recent PATHWAY-2 study.57 At
the same time, we are confident that we have been able to
include all relevant studies reporting 24-h ABPM on MRAs,
RDN and particularly placebo-controlled studies on any treat-
ment strategy30 in the ATRHTN group, and were thus able to
make indirect comparisons between these major strategies for
the treatment of ATRHTN.
More importantly, we could not determine whether the
patients in the individual studies were truly adherent to three
or more antihypertensive medications. This is an important
limitation, as there is evidence suggesting that only half of all
ATRHTN patients fall into the true ATRHTN category, while
the other half may have been misdiagnosed because they did
not fully adhere to medication.11–13 Furthermore, non-
adherence cannot be reliably measured in this population
using self-reported questionnaires,62 requiring urine tests to
monitor adherence.11 This may explain why MRAs are not
notably more effective than sham. While it is likely that
adherence to medication increases during trial conditions, it
is also likely that 100% adherence is not obtained, which may
lead to an underestimation of the treatment effect of
MRA—and all other add-on medication. Consequently, the
results may be driven in part by improved adherence rather
than the true effect of an additional medication.
Another limitation of this network meta-analysis was the
variation in the patient populations among studies, which
could have influenced the results. We adjusted for possible
sources of heterogeneity between studies24 using previously
identified variables such as baseline blood pressure and num-
ber of co-medications used,30 and the results were not sensi-
tive to these variables. However, because of the low number of
studies and the association between covariate levels and treat-
ment strategies, we were not able to use multivariable adjust-
ment techniques in the meta-regression.
In addition, there was substantial use of spironolactone in
both the treatment and control arms of trials that did not
evaluate mineralocorticoid receptor antagonist-based thera-
pies. For example, mineralocorticoid receptor antagonists
were used in 22–28% of patients in the SYMPLICITY
HTN-3 trial, 17% in the SYMPLICITY HTN-2 trial, and
37–45% of patients in the SYMPLICITY HTN-Japan trial.
This contributes to treatment cross-contamination of compar-
ator groups for the indirect pooled comparison of mineralo-
corticoid receptor antagonists with other groups, and may bias
the results towards the null. At the same time, the two moder-
ately large direct comparisons19,20 showed that there was
indeed a small difference between the two treatment alterna-
tives, with only the third, very small study (n = 24) showing
larger differences.47
In terms of network consistency, no significant inconsisten-
cy was found in the RDN–spironolactone–no additional treat-
ment loop. However, a major limitation of this study is that for
most comparisons, there was no combination of direct and
indirect evidence: the network contained only a single closed
loop enabling comparison of direct and indirect treatments.
Therefore, we were only partially able to investigate the con-
sistency of the results; this can be performed fully only if
additional trials are reported directly comparing various treat-
ment strategies in the network, thus closing the network’s
loops.
CONCLUSIONS
Implications for Practice
The only alternative to MRAs which achieved a clinically
meaningful blood pressure reduction of 2 mmHg with high
probability was CAA. However, the results of CAA are based
on a single study, and thus should be interpreted with caution.
Also, CAA has frequent adverse effects; therefore, it may not
be useful in practice. RDN and darusentan were not clinically
different from MRAs.
Implications for Research
Because inconsistency within the network could only be par-
tially assessed, evidence in the field of ATRHTN would ben-
efit from more direct comparisons of various treatments op-
tions, particularly in the case of CAA. In order to improve
comparability between strategies, 24-h ABPM should be used
in such studies, and adherence should be closely monitored to
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ensure that only true treatment-resistant hypertension patients
are included in the trials.
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